Sign Up

NCLA Site Search

Amicus Briefs

Boehringer Ingelheim Pharmaceuticals, Inc. v. HHS

NCLA urges the Second Circuit to rule it is unlawful for HHS to hold a company’s business hostage until it surrenders its constitutional property rights. The law at issue violates the “unconstitutional conditions” doctrine, which prevents the indirect trampling of constitutional rights.

Two years ago, Congress enacted the Inflation Reduction Act of 2022, part of which sought to lower Medicare drug costs. Instead of achieving this important goal lawfully, it chose an approach that cannot be reconciled with the Constitution. The Medicare cost reduction program’s goal is to force pharmaceutical companies to sell their products at less than market value. It cannot do so directly without violating the Takings Clause of the Fifth Amendment. So, it tells companies: Either forfeit your constitutional right or pay excise taxes and penalties on your products that are so draconian they will destroy your business. The U.S. Supreme Court has already spoken to this kind of behavior, choosing the descriptive word “extortion.”

It may be politically popular, albeit short-sighted, to curtail the constitutional rights of big companies, but if Congress can do this to the pharmaceutical companies, then it can do it to mom-and-pop businesses, too. Americans deserve better than a Congress that engages in extortionate behavior, and they have a right to be free of even sophisticated attempts to undermine the Constitution.

Greg Dolin
Senior Litigation Counsel
Daniel Kelly
Senior Litigation Counsel
NCLA FILINGS

Brief Amicus Curiae of the New Civil Liberties Alliance in Support of Plaintiff-Appellant and Reversal

November 8, 2024 | Read More

PRESS RELEASES

NCLA Asks Second Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program

November 8, 2024 | Read More

SHARE THIS CASE

Enter your email address above to be notified whenever we post a new document to this case.